| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
D-Glucosamine 6-phosphate targets the hexosamine biosynthetic pathway and is involved in the regulation of glucose metabolism and cellular signaling. Its phosphorylation state is critical for enzyme activity and influences the production of N-acetylglucosamine-6-phosphate and subsequent biologically relevant molecules. It is a substrate for glucosamine-6-phosphate deaminase and other metabolic enzymes.
|
|---|---|
| ln Vitro |
In vitro, D-Glucosamine 6-phosphate is used to study amino sugar metabolism, protein glycosylation, and glucose metabolism. It can be used as a substrate for enzymes such as glucosamine-6-phosphate deaminase and glucosamine-6-phosphate synthase. Studies have investigated its role in cellular signaling and its effects on glucose metabolism regulation. It is also used in research on diabetes mellitus.
|
| ln Vivo |
In vivo, D-Glucosamine 6-phosphate is an intermediate in the hexosamine biosynthetic pathway and plays a role in glucose metabolism and protein glycosylation. Research on D-glucosamine 6-phosphate reveals insights into normal cellular function and metabolic disorders, deepening the understanding of disease mechanisms. It is not a therapeutic agent but is studied in the context of diabetes and metabolic diseases.
|
| Enzyme Assay |
In vitro enzyme assays with D-Glucosamine 6-phosphate typically involve studying enzymes such as glucosamine-6-phosphate deaminase, glucosamine-6-phosphate synthase, and phosphoglucose isomerase. The compound is used as a substrate to measure enzyme activity. Standard assays involve incubating with enzyme preparations in appropriate buffers and analyzing products by spectrophotometric or chromatographic methods.
|
| Cell Assay |
In vitro cell culture experiments with D-Glucosamine 6-phosphate involve treating cells to study amino sugar metabolism, protein glycosylation, and glucose metabolism. Cells are treated with the compound, and endpoints include assessment of metabolic flux, glycosylation patterns, and gene expression. These experiments are used to study the role of the hexosamine biosynthetic pathway in cellular function and disease.
|
| Animal Protocol |
In vivo animal experiments with D-Glucosamine 6-phosphate are used to study glucose metabolism and metabolic disorders such as diabetes. Animal models are administered the compound or its analogs to study its effects on metabolism and disease progression. These studies provide insights into the role of the hexosamine biosynthetic pathway in normal physiology and disease.
|
| ADME/Pharmacokinetics |
The pharmacokinetic (PK) properties of D-Glucosamine 6-phosphate reflect its role as a metabolic intermediate. As a phosphorylated sugar, it is a polar molecule that does not readily cross cell membranes. It is synthesized intracellularly and metabolized through the hexosamine biosynthetic pathway. Its levels in cells reflect the activity of this pathway and glucose metabolism.
|
| Toxicity/Toxicokinetics |
D-Glucosamine 6-phosphate has a low toxicity profile as it is a naturally occurring metabolic intermediate. It is not considered a hazardous substance. For research use, standard laboratory safety practices are sufficient. Comprehensive toxicology studies have not been published as the compound is a normal cellular metabolite.
|
| References | |
| Additional Infomation |
D-Glucosamine 6-phosphate is a key biochemical compound involved in amino sugar metabolism and protein glycosylation. It is an indispensable intermediate in the hexosamine biosynthetic pathway and is essential for the synthesis of glycosaminoglycans and glycoproteins. The compound is used in research on diabetes mellitus. It is not a drug and has no therapeutic indications, serving as a research tool for studying metabolism and disease mechanisms.
|
| Molecular Formula |
C6H14NO8P
|
|---|---|
| Molecular Weight |
259.15
|
| Exact Mass |
259.046
|
| CAS # |
3616-42-0
|
| Appearance |
White to off-white solid powder
|
| Density |
1.817g/cm3
|
| Boiling Point |
599.3ºC at 760mmHg
|
| Flash Point |
316.2ºC
|
| Index of Refraction |
1.585
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: 250 mg/mL (964.69 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.8588 mL | 19.2938 mL | 38.5877 mL | |
| 5 mM | 0.7718 mL | 3.8588 mL | 7.7175 mL | |
| 10 mM | 0.3859 mL | 1.9294 mL | 3.8588 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
